Keryx Biopharmaceuticals (KERX) 10-Q2017 Q2 Quarterly report

Filed: 27 Jul 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: apparent, death, deposit, equipment, half, heart, leasehold, literature, modification, plaintiff, plant, stay

Removed: achieving, additionally, adequacy, adjusted, advance, analyze, annually, applying, assessment, calculate, capitalization, capitalize, capitalizing, charge, charged, closing, Codification, conclude, contracted, converted, corroborated, coverage, CRO, culmination, decreased, deduct, deducting, defer, define, degree, delayed, delivered, depend, determining, disposal, distribution, distributor, dollar, doubtful, earn, economic, effort, eighteen, element, employee, ending, enrollment, establish, expended, expensed, experienced, extend, external, finite, forfeiture, generated, greater, hierarchy, identical, imminent, impairment, indirect, indirectly, industry, insured, invoice, involved, involvement, labeled, level, licensee, liquid, lower, manufacturer, match, measurable, measure, Medicaid, Medicare, mix, monitored, necessitated, negotiation, obligation, observable, offered, office, original, overhead, participate, participating, past, payment, payor, performed, periodically, permit, predictive, prepaid, program, prompt, quoted, realizable, realization, recoverability, recoverable, redeemed, reduce, reflective, relation, reliability, rely, rendered, reserve, reside, resulting, returned, reviewed, revision, saleable, satisfaction, stated, step, subsequent, substantive, suggest, tablet, tangible, test, trading, uncertain, uncertainty, uncollectible, undiscounted, uneven, unit, unobservable, updated, utilized, vary, wholesale

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

KERX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF

KERYX BIOPHARMACEUTICALS, INC.

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Keryx Biopharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2017 as filed with the Securities and Exchange Commission (the “Report”), I, Gregory P. Madison, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: July 27, 2017	/s/ Gregory P. Madison
	Gregory P. Madison
	Chief Executive Officer
	Principal Executive Officer